论文部分内容阅读
转化淋巴瘤的预后差,主要发生在惰性B细胞淋巴瘤向弥漫性大B细胞淋巴瘤(DLBCL)转化,应用美罗华治疗后可出现CD20抗原表达的丢失,造成耐药和肿瘤进展,文献仅见若干个案报道~([1,2])笔者结合所复习的相关文献资料,报道1例滤泡性淋巴瘤经美罗华联合化疗治疗后转化为弥漫性大B细胞淋巴瘤伴CD20抗原表达的丢失,旨在加深人们对此肿瘤的认识,从而有利于临床优选相应的治
The prognosis of transformed lymphoma is poor, mainly in the conversion of idiopathic B-cell lymphoma to diffuse large B-cell lymphoma (DLBCL). The loss of CD20 antigen expression after treatment with rituximab may lead to drug resistance and tumor progression. Case Report ~ ([1,2]) The author combined with the review of the relevant literature, reported a case of follicular lymphoma treated with rituximab combined with chemotherapy into diffuse large B-cell lymphoma with the loss of CD20 antigen expression To deepen people’s understanding of this tumor, which is conducive to the clinical treatment of the corresponding preferred